Condition
PTCL-NOS
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Not Yet Recruiting1
Active Not Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07724782Phase 1Not Yet RecruitingPrimary
Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL
NCT06137144Phase 1Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT02223208Phase 1Active Not Recruiting
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
Showing all 3 trials